West Pharmaceutical Services (WST) Stock Forecast, Price Target & Predictions
WST Stock Forecast
West Pharmaceutical Services stock forecast is as follows: an average price target of $345.33 (represents a 16.18% upside from WST’s last price of $297.24) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
WST Price Target
The average price target for West Pharmaceutical Services (WST) is $345.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $536.00 to $250.00. This represents a potential 16.18% upside from WST's last price of $297.24.
WST Analyst Ratings
According to 7 Wall Street analysts, West Pharmaceutical Services's rating consensus is 'Buy'. The analyst rating breakdown for WST stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
West Pharmaceutical Services Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 07, 2024 | David Windley | Jefferies | $536.00 | $413.00 | 29.78% | 80.33% |
| Dec 14, 2022 | - | Deutsche Bank | $250.00 | $251.90 | -0.75% | -15.89% |
| Nov 30, 2022 | - | UBS | $250.00 | $222.84 | 12.19% | -15.89% |
The latest West Pharmaceutical Services stock forecast, released on Feb 07, 2024 by David Windley from Jefferies, set a price target of $536.00, which represents a 29.78% increase from the stock price at the time of the forecast ($413.00), and a 80.33% increase from WST last price ($297.24).
West Pharmaceutical Services Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $536.00 |
| Last Closing Price | $297.24 | $297.24 | $297.24 |
| Upside/Downside | -100.00% | -100.00% | 80.33% |
In the current month, the average price target of West Pharmaceutical Services stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to West Pharmaceutical Services's last price of $297.24. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 15, 2024 | William Blair | Outperform | Outperform | Hold |
| Feb 07, 2024 | Jefferies | - | Buy | Upgrade |
| Jun 16, 2023 | Morgan Stanley | - | Buy | Upgrade |
| Jun 16, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Apr 11, 2023 | Stephens | Overweight | Positive | Upgrade |
| Apr 11, 2023 | Stephens | - | Overweight | Upgrade |
| Feb 16, 2023 | William Blair | Outperform | Outperform | Hold |
| Dec 14, 2022 | Deutsche Bank | - | Hold | Initialise |
| Nov 30, 2022 | UBS | - | Neutral | Initialise |
West Pharmaceutical Services's last stock rating was published by William Blair on Feb 15, 2024. The company gave WST a "Outperform" rating, the same as its previous rate.
West Pharmaceutical Services Financial Forecast
West Pharmaceutical Services Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $732.00M | $747.40M | $753.80M | $716.60M | $708.70M | $686.90M | - | $720.00M | $730.80M | $706.50M | $723.60M | $670.70M | $580.20M | $548.00M | $527.20M | $491.50M | $470.60M | $456.10M |
| Avg Forecast | $868.49M | $805.89M | $828.40M | $799.35M | $804.33M | $753.86M | $763.75M | $737.33M | $764.91M | $709.29M | $729.36M | $670.62M | $739.46M | $750.31M | $755.71M | $698.19M | $657.17M | $727.42M | $754.25M | $720.92M | $710.20M | $687.09M | $669.38M | $603.99M | $540.37M | $502.72M | $496.09M | $466.79M | $451.54M | $450.76M |
| High Forecast | $874.37M | $811.36M | $834.02M | $804.77M | $809.78M | $758.97M | $768.93M | $742.33M | $770.10M | $714.47M | $734.31M | $675.17M | $741.36M | $756.26M | $760.84M | $702.93M | $661.62M | $732.35M | $754.25M | $727.49M | $716.66M | $693.35M | $675.48M | $609.48M | $545.29M | $507.29M | $500.60M | $471.04M | $455.65M | $454.87M |
| Low Forecast | $862.01M | $799.88M | $822.22M | $793.39M | $798.33M | $748.24M | $758.06M | $731.83M | $759.21M | $706.42M | $723.92M | $665.62M | $737.76M | $741.00M | $750.08M | $692.99M | $652.26M | $721.99M | $754.25M | $707.39M | $696.86M | $674.19M | $656.82M | $592.65M | $530.22M | $493.28M | $486.77M | $458.03M | $443.06M | $442.30M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.00% | 1.00% | 1.03% | 1.08% | 0.94% | - | 1.00% | 1.03% | 1.03% | 1.08% | 1.11% | 1.07% | 1.09% | 1.06% | 1.05% | 1.04% | 1.01% |
West Pharmaceutical Services's average Quarter revenue forecast for Mar 24 based on 4 analysts is $670.62M, with a low forecast of $665.62M, and a high forecast of $675.17M. WST's average Quarter revenue forecast represents a -8.38% decrease compared to the company's last Quarter revenue of $732.00M (Dec 23).
West Pharmaceutical Services EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $214.00M | $218.60M | $182.50M | $186.90M | $129.70M | $168.90M | - | $216.50M | $218.90M | $219.40M | $250.30M | $210.90M | $149.40M | $133.90M | $135.40M | $117.30M | $108.80M | $94.60M |
| Avg Forecast | $236.46M | $219.42M | $225.55M | $217.64M | $219.00M | $205.25M | $207.95M | $200.75M | $208.26M | $193.12M | $198.58M | $251.13M | $201.33M | $204.29M | $205.76M | $228.30M | $178.93M | $206.48M | $205.36M | $207.54M | $205.22M | $187.71M | $161.40M | $131.41M | $121.64M | $113.81M | $84.81M | $90.12M | $93.69M | $83.94M |
| High Forecast | $238.07M | $220.91M | $227.08M | $219.12M | $220.48M | $206.65M | $209.36M | $202.11M | $209.68M | $194.53M | $199.93M | $301.35M | $201.85M | $205.91M | $207.16M | $273.96M | $180.14M | $247.78M | $205.36M | $249.05M | $246.26M | $225.25M | $193.68M | $157.69M | $145.96M | $136.58M | $101.77M | $108.14M | $112.43M | $100.73M |
| Low Forecast | $234.70M | $217.79M | $223.87M | $216.02M | $217.36M | $203.72M | $206.40M | $199.26M | $206.71M | $192.34M | $197.10M | $200.90M | $200.87M | $201.75M | $204.23M | $182.64M | $177.59M | $165.18M | $205.36M | $166.03M | $164.18M | $150.17M | $129.12M | $105.13M | $97.31M | $91.05M | $67.85M | $72.10M | $74.95M | $67.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.07% | 0.89% | 0.82% | 0.72% | 0.82% | - | 1.04% | 1.07% | 1.17% | 1.55% | 1.60% | 1.23% | 1.18% | 1.60% | 1.30% | 1.16% | 1.13% |
4 analysts predict WST's average Quarter EBITDA for Mar 24 to be $251.13M, with a high of $301.35M and a low of $200.90M. This is 17.35% upper than West Pharmaceutical Services's previous annual EBITDA (Dec 23) of $214.00M.
West Pharmaceutical Services Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $137.00M | $161.30M | $155.10M | $140.00M | $103.00M | $120.60M | - | $173.80M | $147.70M | $175.60M | $187.30M | $151.20M | $98.40M | $82.30M | $91.20M | $74.30M | $63.90M | $56.30M |
| Avg Forecast | $173.20M | $153.38M | $157.41M | $142.82M | $157.82M | $140.01M | $139.20M | $128.39M | $135.30M | $110.60M | $128.33M | $192.44M | $131.05M | $136.84M | $141.97M | $174.95M | $101.39M | $165.26M | $164.01M | $159.04M | $138.47M | $150.24M | $120.78M | $94.21M | $80.11M | $69.95M | $57.13M | $57.08M | $55.02M | $49.96M |
| High Forecast | $174.72M | $154.74M | $158.79M | $144.08M | $159.21M | $141.24M | $140.43M | $129.52M | $136.49M | $117.11M | $129.46M | $230.93M | $136.94M | $142.72M | $143.23M | $209.94M | $102.28M | $198.31M | $164.01M | $190.85M | $166.16M | $180.28M | $144.93M | $113.05M | $96.14M | $83.95M | $68.55M | $68.50M | $66.03M | $59.95M |
| Low Forecast | $171.52M | $151.90M | $155.88M | $141.43M | $156.29M | $138.65M | $137.85M | $127.15M | $133.99M | $106.99M | $127.08M | $153.95M | $127.37M | $132.42M | $140.60M | $139.96M | $100.40M | $132.21M | $164.01M | $127.23M | $110.78M | $120.19M | $96.62M | $75.37M | $64.09M | $55.96M | $45.70M | $45.67M | $44.02M | $39.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.18% | 1.09% | 0.80% | 1.02% | 0.73% | - | 1.09% | 1.07% | 1.17% | 1.55% | 1.60% | 1.23% | 1.18% | 1.60% | 1.30% | 1.16% | 1.13% |
West Pharmaceutical Services's average Quarter net income forecast for Mar 24 is $192.44M, with a range of $153.95M to $230.93M. WST's average Quarter net income forecast represents a 40.47% increase compared to the company's last Quarter net income of $137.00M (Dec 23).
West Pharmaceutical Services SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $90.00M | $89.00M | $88.40M | $86.00M | $85.70M | $66.30M | - | $83.40M | $98.00M | $91.90M | $92.70M | $80.20M | $76.30M | $76.20M | $77.70M | $71.80M | $69.00M | $64.80M |
| Avg Forecast | $112.31M | $104.22M | $107.13M | $103.37M | $104.01M | $97.49M | $98.77M | $95.35M | $98.92M | $91.72M | $94.32M | $92.35M | $95.62M | $97.03M | $97.73M | $83.95M | $84.98M | $86.49M | $97.54M | $76.32M | $91.88M | $78.63M | $59.78M | $49.97M | $62.12M | $64.77M | $48.67M | $55.16M | $59.42M | $57.50M |
| High Forecast | $113.07M | $104.92M | $107.85M | $104.07M | $104.72M | $98.15M | $99.44M | $96.00M | $99.59M | $92.39M | $94.96M | $110.81M | $95.87M | $97.80M | $98.39M | $100.74M | $85.56M | $103.79M | $97.54M | $91.58M | $110.25M | $94.35M | $71.73M | $59.96M | $74.54M | $77.72M | $58.40M | $66.20M | $71.30M | $69.00M |
| Low Forecast | $111.47M | $103.44M | $106.33M | $102.60M | $103.24M | $96.76M | $98.03M | $94.64M | $98.18M | $91.35M | $93.62M | $73.88M | $95.40M | $95.82M | $97.00M | $67.16M | $84.35M | $69.19M | $97.54M | $61.06M | $73.50M | $62.90M | $47.82M | $39.98M | $49.70M | $51.82M | $38.94M | $44.13M | $47.53M | $46.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.92% | 0.90% | 1.02% | 1.01% | 0.77% | - | 1.09% | 1.07% | 1.17% | 1.55% | 1.60% | 1.23% | 1.18% | 1.60% | 1.30% | 1.16% | 1.13% |
West Pharmaceutical Services's average Quarter SG&A projection for Mar 24 is $92.35M, based on 4 Wall Street analysts, with a range of $73.88M to $110.81M. The forecast indicates a 2.61% rise compared to WST last annual SG&A of $90.00M (Dec 23).
West Pharmaceutical Services EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.17 | $2.09 | $1.88 | $1.38 | $1.62 | - | $2.34 | $1.98 | $2.37 | $2.53 | $2.04 | $1.33 | $1.11 | $1.24 | $1.01 | $0.86 | $0.76 |
| Avg Forecast | $2.35 | $2.08 | $2.14 | $1.94 | $2.14 | $1.90 | $1.89 | $1.74 | $1.84 | $1.50 | $1.74 | $1.27 | $1.78 | $1.86 | $1.93 | $1.67 | $1.38 | $2.12 | $2.21 | $2.12 | $1.92 | $1.80 | $1.74 | $1.43 | $1.12 | $0.99 | $0.91 | $0.82 | $0.72 | $0.71 |
| High Forecast | $2.37 | $2.10 | $2.15 | $1.95 | $2.16 | $1.92 | $1.91 | $1.76 | $1.85 | $1.59 | $1.76 | $1.28 | $1.86 | $1.94 | $1.94 | $1.68 | $1.39 | $2.14 | $2.21 | $2.15 | $1.94 | $1.82 | $1.76 | $1.45 | $1.14 | $1.01 | $0.92 | $0.83 | $0.73 | $0.72 |
| Low Forecast | $2.33 | $2.06 | $2.12 | $1.92 | $2.12 | $1.88 | $1.87 | $1.73 | $1.82 | $1.45 | $1.72 | $1.26 | $1.73 | $1.80 | $1.91 | $1.65 | $1.36 | $2.10 | $2.21 | $2.07 | $1.87 | $1.75 | $1.70 | $1.40 | $1.10 | $0.97 | $0.89 | $0.80 | $0.70 | $0.69 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 1.08% | 1.13% | 1.00% | 0.76% | - | 1.10% | 1.03% | 1.32% | 1.45% | 1.43% | 1.18% | 1.12% | 1.37% | 1.23% | 1.19% | 1.07% |
According to 5 Wall Street analysts, West Pharmaceutical Services's projected average Quarter EPS for Dec 23 is $1.78, with a low estimate of $1.73 and a high estimate of $1.86. This represents a -18.06% decrease compared to WST previous annual EPS of $2.17 (Sep 23).
West Pharmaceutical Services Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $106.59 | $298.00 | 179.58% | Buy |
| BAX | Baxter | $38.96 | $64.62 | 65.86% | Hold |
| HAE | Haemonetics | $73.24 | $112.00 | 52.92% | Buy |
| RGEN | Repligen | $147.07 | $189.50 | 28.85% | Buy |
| TFX | Teleflex | $244.53 | $304.09 | 24.36% | Buy |
| BDX | Becton, Dickinson and Company | $232.67 | $280.55 | 20.58% | Buy |
| WST | West Pharmaceutical Services | $297.24 | $345.33 | 16.18% | Buy |
| ALC | Alcon | $94.66 | $93.34 | -1.39% | Buy |
| HOLX | Hologic | $81.57 | $78.92 | -3.25% | Buy |
| MMSI | Merit Medical Systems | $96.58 | $92.13 | -4.61% | Buy |
| RMD | ResMed | $244.87 | $209.33 | -14.51% | Hold |
| ICUI | ICU Medical | $162.32 | $135.00 | -16.83% | Buy |
| EMBC | Embecta | $15.31 | $12.00 | -21.62% | Sell |
WST Forecast FAQ
Is West Pharmaceutical Services a good buy?
Yes, according to 7 Wall Street analysts, West Pharmaceutical Services (WST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of WST's total ratings.
What is WST's price target?
West Pharmaceutical Services (WST) average price target is $345.33 with a range of $250 to $536, implying a 16.18% from its last price of $297.24. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will West Pharmaceutical Services stock go up soon?
According to Wall Street analysts' prediction for WST stock, the company can go up by 16.18% (from the last price of $297.24 to the average price target of $345.33), up by 80.33% based on the highest stock price target, and down by -15.89% based on the lowest stock price target.
Can West Pharmaceutical Services stock reach $400?
WST's highest twelve months analyst stock price target of $536 supports the claim that West Pharmaceutical Services can reach $400 in the near future.
What are West Pharmaceutical Services's analysts' financial forecasts?
West Pharmaceutical Services's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.06B (high $3.08B, low $3.04B), average EBITDA is $832.95M (high $838.6M, low $826.74M), average net income is $565.42M (high $570.4M, low $559.94M), average SG&A $395.61M (high $398.3M, low $392.66M), and average EPS is $7.67 (high $7.74, low $7.6). WST's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.3B (high $3.32B, low $3.28B), average EBITDA is $899.08M (high $905.17M, low $892.37M), average net income is $626.8M (high $632.33M, low $620.73M), average SG&A $427.02M (high $429.92M, low $423.84M), and average EPS is $8.5 (high $8.58, low $8.42).
Did the WST's actual financial results beat the analysts' financial forecasts?
Based on West Pharmaceutical Services's last annual report (Dec 2023), the company's revenue was $2.95B, beating the average analysts forecast of $2.94B by 0.21%. Apple's EBITDA was $875.7M, beating the average prediction of $839.68M by 4.29%. The company's net income was $593.4M, beating the average estimation of $584.81M by 1.47%. Apple's SG&A was $353.4M, missing the average forecast of $374.33M by -5.59%. Lastly, the company's EPS was $7.98, beating the average prediction of $7.23 by 10.38%. In terms of the last quarterly report (Dec 2023), West Pharmaceutical Services's revenue was $732M, missing the average analysts' forecast of $739.46M by -1.01%. The company's EBITDA was $214M, beating the average prediction of $201.33M by 6.29%. West Pharmaceutical Services's net income was $137M, beating the average estimation of $131.05M by 4.54%. The company's SG&A was $90M, missing the average forecast of $95.62M by -5.88%. Lastly, the company's EPS was $0, missing the average prediction of $1.78 by -100.00%